NO20065480L - Vaksiner. - Google Patents

Vaksiner.

Info

Publication number
NO20065480L
NO20065480L NO20065480A NO20065480A NO20065480L NO 20065480 L NO20065480 L NO 20065480L NO 20065480 A NO20065480 A NO 20065480A NO 20065480 A NO20065480 A NO 20065480A NO 20065480 L NO20065480 L NO 20065480L
Authority
NO
Norway
Prior art keywords
antigen
vaccines
eso
saponin
adjuvant
Prior art date
Application number
NO20065480A
Other languages
English (en)
Norwegian (no)
Inventor
Remi M Palmantier
Claudine Elvire Marie Bruck
Vincent Brichard
Melinda Meaders
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20065480L publication Critical patent/NO20065480L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20065480A 2004-05-04 2006-11-28 Vaksiner. NO20065480L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409940.4A GB0409940D0 (en) 2004-05-04 2004-05-04 Vaccine
PCT/EP2005/004956 WO2005105139A2 (fr) 2004-05-04 2005-05-02 Vaccins

Publications (1)

Publication Number Publication Date
NO20065480L true NO20065480L (no) 2006-11-28

Family

ID=32482653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065480A NO20065480L (no) 2004-05-04 2006-11-28 Vaksiner.

Country Status (16)

Country Link
US (1) US20070243196A1 (fr)
EP (1) EP1755657A2 (fr)
JP (1) JP2007536326A (fr)
CN (1) CN1980691A (fr)
AU (1) AU2005237256A1 (fr)
BR (1) BRPI0510570A (fr)
CA (1) CA2564470A1 (fr)
GB (1) GB0409940D0 (fr)
IL (1) IL178681A0 (fr)
MA (1) MA28639B1 (fr)
MX (1) MXPA06012723A (fr)
NO (1) NO20065480L (fr)
NZ (1) NZ550967A (fr)
RU (1) RU2006138283A (fr)
WO (1) WO2005105139A2 (fr)
ZA (1) ZA200608693B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653402A1 (fr) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals S.A. Methode
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
ES2398492T3 (es) * 2007-01-15 2013-03-19 Glaxosmithkline Biologicals Sa Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
EP2457928B1 (fr) 2007-03-13 2017-05-10 Universität Zürich Anticorps monoclonal humain spécifique d'une tumeur
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
WO2009127666A2 (fr) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Procédé et compositions
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
SG174877A1 (en) 2009-03-17 2011-11-28 Mdxhealth Sa Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2617983T3 (es) * 2011-01-10 2017-06-20 Ct Atlantic Ltd. Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
EP3024936B1 (fr) 2013-07-25 2019-09-04 Exicure, Inc. Constructions à partir d'acides nucléiques sphériques utilisées en tant qu'agents immunostimulants à des fins prophylactiques et thérapeutiques
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
WO2016019298A2 (fr) * 2014-08-01 2016-02-04 Texas Tech University System Protéine de sperme 17 antigène testiculaire du cancer utilisée en tant que cible pour l'immunothérapie et le diagnostic du cancer du sein
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2018039629A2 (fr) 2016-08-25 2018-03-01 Northwestern University Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018226931A1 (fr) * 2017-06-07 2018-12-13 David Weiner Vaccins mage-a et méthodes de traitement les utilisant
WO2019061297A1 (fr) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 Peptide de fusion d'épitope de lymphocyte t auxiliaire cd4 et vaccin associé
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
JP2000506279A (ja) * 1996-02-23 2000-05-23 ブリティッシュ・テレコミュニケーションズ・パブリック・リミテッド・カンパニー 光相互接続
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens

Also Published As

Publication number Publication date
WO2005105139A3 (fr) 2006-04-13
CN1980691A (zh) 2007-06-13
RU2006138283A (ru) 2008-06-10
NZ550967A (en) 2009-01-31
AU2005237256A1 (en) 2005-11-10
BRPI0510570A (pt) 2007-11-20
CA2564470A1 (fr) 2005-11-10
EP1755657A2 (fr) 2007-02-28
JP2007536326A (ja) 2007-12-13
GB0409940D0 (en) 2004-06-09
WO2005105139A2 (fr) 2005-11-10
IL178681A0 (en) 2007-02-11
ZA200608693B (en) 2010-01-27
US20070243196A1 (en) 2007-10-18
MA28639B1 (fr) 2007-06-01
MXPA06012723A (es) 2007-02-14

Similar Documents

Publication Publication Date Title
NO20065480L (no) Vaksiner.
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
NO20090897L (no) Vaksine
WO2006042254A3 (fr) Adjuvant pour vaccin a adn
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
ATE474931T1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
WO2016207853A3 (fr) Vaccins contre la grippe à correspondance antigénique
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
TW200722101A (en) Novel composition
ATE542829T1 (de) Impfstoff
NO20072253L (no) Forbedrede vaksiner
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
GB0123580D0 (en) Vaccine
CR6880A (es) Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis
CY1116904T1 (el) Εμβολιο
UY31285A1 (es) Vacunas
GB2386072A (en) Novel vaccine
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
ATE392216T1 (de) Mycobakterieller impfstoff
DK1350839T3 (da) Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti
WO2007052165A3 (fr) Vaccin a base de vecteur lentiviral
DE60336927D1 (fr)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application